May 31, 2024 Sophia Vida
Breaking News

Lipella Pharmaceuticals Announces Completion of Site Initiation Visit for Phase 2a Trial of LP-310 in Oral Lichen Planus

Clinical testing of LP-310 expected to commence in mid-2024    Patient recruitment is underway for Phase 2a multicenter, dose-ranging study PITTSBURGH, PA., May 31, 2024 — Lipella Pharmaceuticals Inc. (Nasdaq: LIPO) (“Lipella,” “our,” “us” or the “Company”), a clinical-stage biotechnology company addressing serious diseases with significant unmet need, today announced the successful completion of its first … Continue reading “Lipella Pharmaceuticals Announces Completion of Site Initiation Visit for Phase 2a Trial of LP-310 in Oral Lichen Planus”